Last reviewed · How we verify
Genfleet Therapeutics (Shanghai) Inc. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
3 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| GFH375 | GFH375 | phase 3 | PI3K delta inhibitor | PI3K delta | Immunology |
Therapeutic area mix
- Immunology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- AmMax Bio, Inc. · 1 shared drug class
- Aronora, Inc. · 1 shared drug class
- Astellas Pharma Europe B.V. · 1 shared drug class
- Astellas Pharma Global Development, Inc. · 1 shared drug class
- Astellas Pharma Inc · 1 shared drug class
- AstraZeneca · 1 shared drug class
- Axikin Pharmaceuticals, Inc. · 1 shared drug class
- Addpharma Inc. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Genfleet Therapeutics (Shanghai) Inc.:
- Genfleet Therapeutics (Shanghai) Inc. pipeline updates — RSS
- Genfleet Therapeutics (Shanghai) Inc. pipeline updates — Atom
- Genfleet Therapeutics (Shanghai) Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Genfleet Therapeutics (Shanghai) Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/genfleet-therapeutics-shanghai-inc. Accessed 2026-05-18.